Why the popular sleep aid zopiclone is often no better than older benzodiazepines
In short: Marketed as a safer alternative to traditional sedatives, zopiclone is a cyclopyrrolone drug that mimics the addictive profile of benzodiazepines. Despite its popularity, it offers no clinically significant increase in total sleep time, carries risks of dependence, and impairs next-day motor coordination, making it a controversial choice for insomnia.
Introduced in 1986 by Rhône-Poulenc S.A., zopiclone was initially promoted as a superior improvement over benzodiazepines. However, subsequent research has largely disproven this claim. Pharmacologically, zopiclone functions as a full agonist at the benzodiazepine site of GABAA receptors, sharing an nearly identical profile with benzodiazepines. It is a central nervous system depressant that, while reducing sleep latency by 10 to 20 minutes, fails to provide a clinically significant increase in total sleep duration—defined as at least 30 minutes.
The drug's risks are substantial. Tolerance and dependence can develop within days to weeks, and long-term use is associated with cognitive impairment, anterograde amnesia, and a heightened risk of falls, particularly in the elderly. Furthermore, zopiclone significantly impairs psychomotor function, leading to a 50% increase in the risk of motor vehicle accidents. These effects can carry over to the next day, impacting hand-eye coordination and driving ability. Because of these dangers, medical guidelines generally restrict its use to short-term treatment, typically no longer than 2 to 4 weeks.
The clinical reality is that non-drug interventions, such as cognitive behavioral therapy, have been found superior to zopiclone, offering lasting benefits for sleep quality for at least a year. In the United States, zopiclone is not commercially available; instead, the active stereoisomer eszopiclone is marketed. Globally, zopiclone remains a controlled substance in many jurisdictions due to its potential for misuse, addiction, and its frequent appearance in cases of drug-impaired driving. Its interaction with alcohol and other CNS depressants further elevates the risk of fatal overdose, reinforcing the consensus that it should be used with extreme caution.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Zopiclone
To cite this card, link to https://intellectplus.co.uk/app/technology-zopiclone.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in UK & Ireland: inventions · More in Technology · Latest · A–Z · All topics